1. What Is the Hyperthyroidism Market?
The Hyperthyroidism Market covers the antithyroid drugs, the radioiodine ablation services, and the thyroid surgery used to manage the overactive thyroid gland. The Graves' disease autoimmune stimulation, the toxic multinodular goitre autonomous nodule secretion, and the toxic adenoma create the excessive thyroid hormone production. The tachycardia, the palpitations, the weight loss, the heat intolerance, and the tremor arise from the sympathomimetic effects of the excess T3 and T4 on the cardiovascular and the metabolic targets. Hyperthyroidism pharmacological treatment uses the thionamide antithyroid drugs methimazole and propylthiouracil that block the thyroid peroxidase enzyme that organifies the iodide to form the thyroid hormone. The PTU additionally blocks the peripheral T4-to-T3 conversion that the methimazole does not provide. The thyroid storm management requires the PTU for the rapid T3 level reduction. The hyperthyroidism market is advancing with the teprotumumab IGF-1R antibody for the Graves' ophthalmopathy. The FDA-approved antibody reduced the orbital fibroblast activation and the proptosis by 71 percent versus 20 percent placebo in the OPTIC trial.
2. Hyperthyroidism Market Size & Forecast
3. Emerging Technologies
- Methimazole versus propylthiouracil selection in hyperthyroidism prefers the methimazole for the non-pregnant patient from the once-daily dosing convenience and the lower hepatotoxicity risk. The PTU carries the agranulocytosis and the vasculitis and the severe hepatotoxicity at a higher rate. The PTU is preferred for the first trimester pregnancy where the methimazole embryopathy including the aplasia cutis and the choanal atresia justifies the PTU switch during organogenesis.
- Radioiodine I-131 ablation achieves the permanent hypothyroidism in 70 to 90 percent of the treated Graves' disease patients at the ablative dose. The Graves' ophthalmopathy worsening in 15 percent of the patients who smoke or who have the moderate-to-severe eye disease provides the ophthalmopathy consideration. The consideration contraindicated the radioiodine in the active GO patient without the steroid cover.
- Teprotumumab Tepezza IGF-1R antibody for the moderate-to-severe active Graves' ophthalmopathy OPTIC Phase III demonstrated 71 percent proptosis responder rate versus 20 percent placebo at 24 weeks. The disease-specific treatment reduces the orbital proptosis. The treatment avoids the surgical orbital decompression that the severe proptosis previously required.
- Beta-blocker propranolol or atenolol for the symptomatic management of the thyrotoxic tachycardia and the tremor during the initial antithyroid drug treatment provides the rapid symptom control. The antithyroid drug treatment requires 4 to 8 weeks before achieving the euthyroid state. The thionamide alone cannot achieve the symptom control in the immediate term.
Similar technologies are also transforming adjacent markets. Learn more in our Hypothyroidism Market.
4. Key Market Opportunity
Material revenue potential in the Hyperthyroidism market is teprotumumab expansion in Graves' thyroid eye disease, where the IGF-1R inhibitor's major proptosis reduction drives prescribing growth in this previously poorly-treated condition. Amgen (acquired Horizon) capturing teprotumumab commercial expansion captures this major thyroid eye disease opportunity. Additional momentum is centered on TSH receptor antibody-targeted therapy for Graves' disease pathogenesis. As teprotumumab adoption proceeds and TSH receptor-targeted programmes develop, the addressable opportunity is evolving from thioamide-and-radioiodine standard hyperthyroidism management toward targeted Graves' disease therapy.
5. Top Companies in the Hyperthyroidism Market
The following organisations hold leading positions in the Hyperthyroidism Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- GSK
- Sun Pharma
- Cipla
- Sanofi
- Viatris
- Lannett
- Eisai
6. Market Segmentation
The Hyperthyroidism Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Treatment | Thioamide Radioactive Iodine Beta-Blocker Surgery |
| By Drug | Methimazole Propylthiouracil |
| By Etiology | Graves' Disease Toxic Nodular Goiter Thyroiditis |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Hyperthyroidism Market trajectory over the forecast period:
Teprotumumab Tepezza IGF-1R Antibody OPTIC Phase III 71 Percent Proptosis Responder Rate Versus 20 Percent Placebo in Moderate-to-Severe Active Graves' Ophthalmopathy Has Provided the Disease-Specific Treatment Reducing Orbital Proptosis Without Surgical Decompression.Generic methimazole from multiple manufacturers is preferred over propylthiouracil as the first-line antithyroid drug in all patients except during the first trimester of pregnancy, where PTU's lower teratogenicity risk relative to methimazole's embryopathic association with aplasia cutis and other defects justifies the switch for pregnancy-eligible women. The 40-50% long-term remission rate after 12-18 months of methimazole defines the clinical success ceiling of antithyroid drug therapy, with the remaining 50-60% of patients ultimately requiring definitive treatment with radioactive iodine or thyroidectomy. Novel immunomodulatory approaches targeting the TRAb autoantibody that drives Graves disease are in Phase 2 development from Immunovant and others, offering the prospect of disease-modifying therapy that could improve remission rates beyond the 50% ceiling of antithyroid drug alone.
Methimazole First-Trimester Embryopathy Including Aplasia Cutis and Choanal Atresia Mandating the Switch to PTU During Organogenesis Has Established the Trimester-Dependent Antithyroid Drug Selection Protocol That Pregnancy Hyperthyroidism Management Requires.Immunovant's batoclimab reduces immunoglobulin levels by blocking FcRn-mediated IgG recycling, providing a mechanism that specifically reduces the TRAb autoantibodies responsible for thyroid-stimulating receptor activation in Graves disease without general immunosuppression. Phase 2 IMVT-1402 data in Graves thyroid disease demonstrated 84% reduction in TRAb levels and 57% TRAb normalisation after 24 weeks of subcutaneous injection, providing the strongest immunological signal of any Graves disease drug candidate. The commercial opportunity for a remission-inducing Graves disease treatment is substantial given that Graves affects approximately 3 million people in the US and that the current treatment algorithm requires years of antithyroid drug therapy before achieving the durable remission that avoids definitive ablative therapy.
Radioiodine I-131 Ablation 70 to 90 Percent Permanent Hypothyroidism in Graves' Disease With Active Ophthalmopathy Worsening Risk in Smokers Has Established the Contraindication That Requires Antithyroid Drug or Surgery as the Preferred Treatment for the Active GO Patient.Amgen's teprotumumab Tepezza generated USD 1.4 billion in 2024 revenue for moderate-to-severe active thyroid eye disease, the autoimmune orbital complication occurring in approximately 50% of Graves disease patients that can cause severe proptosis, diplopia, and visual impairment. The mechanism of IGF-1R and TSH receptor co-signalling in orbital fibroblasts that is blocked by teprotumumab connects hyperthyroidism's autoimmune pathophysiology to the orbital tissue expansion of TED, establishing a pharmacological approach to a condition previously managed only with corticosteroids, orbital radiation, or decompressive surgery. Roche's rozanolixizumab FcRn antagonist and Immunovant's IMVT-1402 are advancing in TED as alternatives to teprotumumab with potentially improved tolerability profiles, creating competition in an indication that Amgen currently occupies as the sole approved mechanism.
For related market intelligence, see the Thyroid Disorder Market.
8. Segmental Analysis
By treatment, the antithyroid drug segment dominated the Hyperthyroidism Market in 2025, as genericised methimazole and propylthiouracil anchored first-line medical management of Graves disease and toxic nodular goitre, generating the largest treatment volume across the diagnosed population in the indication.
By etiology, the Graves disease segment is projected to register the highest growth rate through 2034, as emerging immunomodulatory and thyroid-stimulating-hormone-receptor-targeted therapies pursue disease modification beyond the symptomatic control offered by existing antithyroid drugs and definitive radioactive iodine.
9. Regional Analysis
Regional demand patterns across the Hyperthyroidism Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Hyperthyroidism Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for teprotumumab Graves' ophthalmopathy and established methimazole prescribing for hyperthyroidism. Moreover, teprotumumab launch is concentrated in the US market. In addition, radioactive iodine therapy use is established. Regional dominance is due to this combination of pricing environment and teprotumumab launch.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Hyperthyroidism Market through 2034, driven by expanding teprotumumab access across European healthcare systems and the established European hyperthyroidism management with methimazole and radioactive iodine. The region is also witnessing TSH receptor-targeted Graves' programmes advancing. Moreover, Graves' ophthalmopathy diagnosis is expanding. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Hyperthyroidism Market was valued at USD 1.78 Bn in 2025 and is projected to reach USD 3.06 Bn by 2034, growing at a CAGR of 6.2% over the 2026–2034 forecast period.
The Hyperthyroidism Market is projected to grow at a CAGR of 6.2% from 2026 to 2034.
North America dominated the Hyperthyroidism Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for teprotumumab Graves' ophthalmopathy and established methimazole prescribing for hyperthyroidism.
The leading companies in the Hyperthyroidism Market include Pfizer, GSK, Sun Pharma, Cipla, Sanofi, Viatris, Lannett, Eisai.
Teprotumumab tepezza igf-1r antibody optic phase iii 71 percent proptosis responder rate versus 20 percent placebo in moderate-to-severe active graves' ophthalmopathy has provided the disease-specific treatment reducing orbital proptosis without surgical decompression.
By treatment, the antithyroid drug segment dominated the Hyperthyroidism Market in 2025, as genericised methimazole and propylthiouracil anchored first-line medical management of Graves disease and toxic nodular goitre, generating the largest treatment volume across the diagnosed population in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.